# Envista Holdings Corp: Form 10-Q for the period ended Jun 30, 2023

- Company: [Envista Holdings Corp](/companies/nvst.md) (CIK 1757073)
- Form: 10-Q
- Filed: 2023-08-02
- Accepted by EDGAR: Aug 2, 2023, 16:24 ET
- Period: 2023-06-30
- Accession: 0001757073-23-000060
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1757073/000175707323000060/nvst-20230630.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1757073/000175707323000060/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2023-06-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2023-04-01 to 2023-06-30 | $662.4m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 6 months, 2023-01-01 to 2023-06-30 | $1.29bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months, 2023-04-01 to 2023-06-30 | $283.8m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 6 months, 2023-01-01 to 2023-06-30 | $548.3m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months, 2023-04-01 to 2023-06-30 | $378.6m | us-gaap:GrossProfit |
| Gross profit | 6 months, 2023-01-01 to 2023-06-30 | $741.3m | us-gaap:GrossProfit |
| Research and development | 3 months, 2023-04-01 to 2023-06-30 | $26.8m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months, 2023-01-01 to 2023-06-30 | $51.3m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months, 2023-04-01 to 2023-06-30 | $272.9m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months, 2023-01-01 to 2023-06-30 | $539.0m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2023-04-01 to 2023-06-30 | $78.9m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months, 2023-01-01 to 2023-06-30 | $151.0m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2023-04-01 to 2023-06-30 | $17.4m | us-gaap:InterestExpense |
| Interest expense | 6 months, 2023-01-01 to 2023-06-30 | $34.1m | us-gaap:InterestExpense |
| Income tax | 3 months, 2023-04-01 to 2023-06-30 | $16.7m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months, 2023-01-01 to 2023-06-30 | $28.6m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2023-04-01 to 2023-06-30 | $51.9m | us-gaap:NetIncomeLoss |
| Net income | 6 months, 2023-01-01 to 2023-06-30 | $95.7m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2023-04-01 to 2023-06-30 | $0.29 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months, 2023-01-01 to 2023-06-30 | $0.54 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2023-04-01 to 2023-06-30 | $0.32 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months, 2023-01-01 to 2023-06-30 | $0.58 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2023-04-01 to 2023-06-30 | 176,300,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months, 2023-01-01 to 2023-06-30 | 176,900,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months, 2023-01-01 to 2023-06-30 | $78.2m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months, 2023-01-01 to 2023-06-30 | $31.6m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2023-06-30 | $651.7m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2023-06-30 | $1.49bn | us-gaap:AssetsCurrent |
| Total assets | at 2023-06-30 | $6.61bn | us-gaap:Assets |
| Current liabilities | at 2023-06-30 | $1.15bn | us-gaap:LiabilitiesCurrent |
| Long-term debt | at 2023-06-30 | $875.6m | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | at 2023-06-30 | $511.5m | us-gaap:DebtCurrent |
| Short-term borrowings | at 2023-06-30 | $511.5m | us-gaap:ShortTermBorrowings |

## Management's discussion and analysis

As filed, 43,696 characters.

*The following discussion and analysis of our financial condition and results of operations should be read in conjunction with other information, including our Condensed Consolidated Financial Statements and related notes included in Part I, Item 1, Financial Information, of this Quarterly Report on Form 10-Q, our consolidated financial statements appearing in our Annual Report on Form 10-K for the year ended December 31, 2022 (the “2022 10-K”), and Part II, Item 1A, Risk Factors, of this Quarterly Report on Form 10-Q. Unless the context otherwise requires, all references herein to the “Company,” “we,” “us” or “our,” or similar terms, refer to Envista Holdings Corporation and its consolidated subsidiaries.*

*Certain statements included or incorporated by reference in this Quarterly Report are “forward-looking statements” within the meaning of the U.S. federal securities laws. All statements other than historical factual information are forward-looking statements, including without limitation statements regarding: the potential impacts of the COVID-19 pandemic on our business, financial condition, and results of operations; projections of revenue, expenses, profit, profit margins, tax rates, tax provisions, cash flows, pension and benefit obligations and funding requirements, our liquidity position or other projected financial measures; management’s plans and strategies for future operations, including statements relating to anticipated operating performance, cost reductions, restructuring activities, new product and service developments, competitive strengths or market position, acquisitions and the integration thereof, divestitures, spin-offs, split-offs or other distributions, strategic opportunities, securities offerings, stock repurchases, dividends and executive compensation; growth, declines and other trends in markets we sell into; future regulatory approvals and the timing thereof; outstanding claims, legal proceedings, tax audits and assessments and other contingent liabilities; future foreign currency exchange rates and fluctuations in those rates; the anticipated timing of any of the foregoing; assumptions underlying any of the foregoing; and any other statements that address events or developments that Envista intends or believes will or may occur in the future. Terminology such as “believe,” “anticipate,” “should,” “could,” “intend,” “will,” “plan,” “expect,” “estimate,” “project,” “target,” “may,” “possible,” “potential,” “forecast” and “positioned” and similar references to future periods are intended to identify forward-looking statements, although not all forward-looking statements are accompanied by such words. Forward-looking statements are based on assumptions and assessments made by our management in light of their experience and perceptions of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. These forward-looking statements are subject to a number of risks and uncertainties, including but not limited to, the following: the conditions in the U.S. and global economy, the impact of inflation and increasing interest rates, international economic, political, legal, compliance and business factors, the markets served by us and the financial markets, the impact of the COVID-19 pandemic, the impact of our debt obligations on our operations and liquidity, developments and uncertainties in trade policies and regulations, contractions or growth rates and cyclicality of markets we serve, risks relating to product manufacturing, commodity costs and surcharges, our ability to adjust purchases and manufacturing capacity to reflect market conditions, reliance on sole or limited sources of supply, disruptions relating to war, terrorism, climate change, widespread protests and civil unrest, man-made and natural disasters, public health issues and other events, security breaches or other disruptions of our information technology systems or violations of data privacy laws, fluctuations in inventory of our distributors and customers, loss of a key distributor, our relationships with and the performance of our channel partners, competition, our ability to develop and successfully market new products and services, our ability to attract, develop and retain our key personnel, the potential for improper conduct by our employees, agents or business partners, our compliance with applicable laws and regulations (including regulations relating to medical devices and the health care industry), the results of our clinical trials and perceptions thereof, penalties associated with any off-label marketing of our products, modifications to our products that require new marketing clearances or authorizations, our ability to effectively address cost reductions and other changes in the health care industry, our ability to successfully identify and consummate appropriate acquisitions and strategic investments, our ability to integrate the businesses we acquire and achieve the anticipated benefits of such acquisitions, contingent liabilities relating to acquisitions, investments and divestitures, our ability to adequately protect our intellectual property, the impact of our restructuring activities on our ability to grow, risks relating to currency exchange rates, changes in tax laws applicable to multinational companies, litigation and other contingent liabilities including intellectual property and environmental, health and safety matters, risks relating to product, service or software defects, the impact of regulation on demand for our products and services, and labor matters, and other risks and uncertainties set forth under “Item 1A. Risk Factors” in the 2022 10-K and this Quarterly Report on Form 10-Q.*

*Forward-looking statements are not guarantees of future performance and actual results may differ materially from the results, developments and business decisions contemplated by our forward-looking statements. Accordingly, you should not place undue reliance on any such forward-looking statements. Forward-looking statements contained herein speak only as of the date of this Quarterly Report. Except to the extent required by applicable law, we do not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise.*

### BASIS OF PRESENTATION

The accompanying Condensed Consolidated Financial Statements present our historical financial position, results of operations, changes in stockholders’ equity and cash flows in accordance with GAAP.

### Sale of the KaVo Treatment Unit and Instrument Business

On December 31, 2021, we sold substantially all of the KaVo Treatment Unit and Instrument Business (the “Divestiture”) to planmeca Verwaltungs Gmbh, Germany (“Planmeca”), pursuant to the master sale and purchase agreement (the “Purchase Agreement”) among us, Planmeca, and Planmeca Oy, as guarantor. However, the transfer of assets in certain countries was not executed and closed until 2022 (“Deferred Local Closing”). As of December 31, 2022, all Deferred Local Closings were completed and we received total net cash consideration of $386.4 million in accordance with the terms of the Purchase Agreement.

The Divestiture was part of our strategy to structurally improve our long-term margins and represented a strategic shift with a major effect on our operations and financial results as described in ASC 205-20. The sale met the criteria to be accounted for as a discontinued operation and therefore, we applied discontinued operations treatment for the Divestiture as required by ASC 205-20. In accordance with ASC 205-20, we have reported the financial results of the Divestiture as discontinued operations in our Condensed Consolidated Statements of Operations and have excluded the KaVo Treatment Unit and Instrument Business from all segment information and descriptions for the three and six months ended July 1, 2022. Our Condensed Consolidated Statements of Cash Flows include the financial results of the KaVo Treatment Unit and Instrument Business for the six months ended July 1, 2022. As all Deferred Local Closings were completed as of December 31, 2022, there are no discontinued operations reported for the three and six months ended June 30, 2023.

### OVERVIEW

### General

We provide products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, as well as to improve the aesthetics of the human smile. We help our customers deliver the best possible patient care through industry-leading solutions, technologies, and services. With leading brand names, innovative technology and significant market positions, we are a leading worldwide provider of a broad range of solutions to support implant-based tooth replacements, orthodontic treatments, digital imaging and diagnostics, as well as general dental consumables, equipment and services, and are dedicated to driving technological innovations that help dental professionals improve clinical outcomes and enhance productivity. Our research and development, manufacturing, sales, distribution, service and administrative facilities are located in more than 30 countries across North America, Asia, Europe, the Middle East and Latin America.

We operate in two business segments: Specialty Products & Technologies and Equipment & Consumables. Our Specialty Products & Technologies segment develops, manufactures and markets products primarily related to dental implant systems, including regenerative solutions, dental prosthetics and associated treatment software and technologies, as well as orthodontic bracket systems, aligners and lab products. Our Equipment & Consumables segment develops, manufactures and markets products primarily related to dental equipment and supplies used in dental offices, including digital imaging systems, software and other visualization/magnification systems; endodontic systems and related consumables; and restorative materials and instruments, rotary burs, impression materials, bonding agents and cements and infection prevention products.

For the three and six months ended June 30, 2023, sales derived from customers outside of the United States were 52.7% and 52.5%, respectively, compared to both the three and six months ended July 1, 2022, of 51.3%. As a global provider of dental consumables, equipment and services, our operations are affected by worldwide, regional and industry-specific economic and political factors. Given the broad range of dental products, software and services provided and geographies served, we do not use any indices other than general economic trends to predict our overall outlook. Our individual businesses monitor key competitors and customers, including to the extent possible their sales, to gauge relative performance and the outlook for the future.

As a result of our geographic and product line diversity, we face a variety of opportunities and challenges, including rapid technological development in most of our served markets, the expansion and evolution of opportunities in emerging markets, trends and costs associated with a global labor force, consolidation of our competitors and increasing regulation. We operate in a highly competitive business environment in most markets, and our long-term growth and profitability will depend in particular on our ability to expand our business in emerging geographies and market segments, identify, consummate and integrate appropriate acquisitions, develop innovative and differentiated new products and services, expand and improve the effectiveness of our sales force, continue to reduce costs and improve operating efficiency and quality and effectively address the demands of an increasingly regulated global environment. We are making significant investments to address the rapid pace of technological change in our served markets and to globalize our manufacturing, research and development and customer-facing resources (particularly in emerging markets and our dental implant business) in order to be responsive to our customers throughout the world and improve the efficiency of our operations.

### Key Trends and Conditions Affecting Our Results of Operations

There have been no material changes to the key trends and conditions affecting our results of operations that were disclosed in our 2022 10-K, except as follows:

### Foreign Currency Exchange Rates

On a period-over-period basis, currency exchange rates negatively impacted reported sales by 1.2% and 1.4% for the three and six months ended June 30, 2023, respectively, compared to the comparable period of 2022, primarily due to the strength of the U.S. dollar against most major currencies. Any future strengthening of the U.S. dollar against major currencies would negatively impact our sales and results of operations for the remainder of the year, and any weakening of the U.S. dollar against major currencies would positively impact our sales and results of operations for the remainder of the year.

### General Economic Conditions

In addition to industry-specific factors, we, like other businesses, face challenges related to global economic conditions, including rising inflation, increasing interest rates, fluctuating foreign currency exchange rates, slowing economic growth, and continuing supply chain disruptions. Dental costs are largely out-of-pocket for the consumer and thus utilization rates can vary significantly depending on economic growth. While many of our products are considered necessary by patients regardless of the economic environment, certain products and services that support discretionary dental procedures may be more susceptible to changes in economic conditions.

### Pricing Controls

Certain countries, as well as some private payors, control the price of health care products, directly or indirectly, through reimbursement, payment, pricing or coverage limitations, tying reimbursement to outcomes or (in the case of governmental entities) compulsory licensing. For example, China has implemented volume-based procurement policies, a series of centralized reforms instituted in China on both a national and regional basis that has resulted in significant price cuts for medical and dental consumables.

### Russia-Ukraine Conflict

Russia’s invasion of Ukraine and the global response to this invasion, including sanctions imposed by the U.S. and other countries, could have an adverse impact on our business, including our ability to market and sell products in the affected regions, potentially heightening our risk of cyber security attacks, impacting our ability to enforce our intellectual property rights in Russia, creating disruptions in the global supply chain, and potentially having an adverse impact on the global economy, financial markets, energy markets, currency rates and otherwise. While we are experiencing some volatility in sales from this region, Russia’s invasion of Ukraine did not have a material impact on our overall financial position or results of operations as of and for the three and six months ended June 30, 2023 and July 1, 2022.

### COVID-19

The extent of the impact of the COVID-19 pandemic on our business remains uncertain and difficult to predict because of the dynamic and evolving nature of the situation. The global impact of the outbreak continues to adversely affect many industries, and different geographies continue to reflect the effects of public health restrictions in various ways. The economic recovery following the impact of the COVID-19 pandemic is only partially underway and has been gradual, uneven and characterized by meaningful dispersion across sectors and regions with uncertainty regarding its ultimate length and trajectory. During the three and six months ended June 30, 2023, notwithstanding improvement in many markets in which we operate due to a return to more normalized business operations, certain markets continued to be adversely impacted by COVID-19.

For additional information on certain risks to our business, please refer to the “Item 1A. Risk Factors” section of our 2022 10-K.

### Acquisitions

Our growth strategy contemplates future acquisitions and we continually evaluate potential acquisitions that either strategically fit with our existing portfolio or expand our portfolio into new and attractive business areas. Our operations and results can be affected by the rate and extent to which appropriate acquisition opportunities are available, acquired businesses are effectively integrated and anticipated synergies or cost savings are achieved. During the fiscal year 2022, we completed two acquisitions.

On July 5, 2022, we acquired all of the equity of Osteogenics for total consideration of approximately $128.2 million, subject to certain customary adjustments as provided in the Equity Purchase Agreement dated May 17, 2022. Osteogenics develops innovative regenerative solutions for periodontists, oral and maxillofacial surgeons, and clinicians involved in implant dentistry throughout the world, and is part of our Specialty Products & Technologies segment.

On April 20, 2022, we completed our acquisition of Carestream Dental’s Intraoral Scanner Business for total consideration of approximately $580.3 million, including contingent consideration of $7.5 million, and subject to certain customary adjustments as provided in the IOS Purchase Agreement. The Intraoral Scanner Business manufactures, markets, sells, commercializes, distributes, services, trains, supports, and maintains operations of intraoral scanners and software, and is part of our Equipment & Consumables segment. We purchased the Intraoral Scanner Business through the acquisition of certain assets and the assumption of certain liabilities as well as the acquisition of all of the equity of certain subsidiaries of Carestream Dental.

### Envista Business Systems

Throughout this discussion, references to sales volume refer to the impact of both price and unit sales and references to productivity improvements generally refer to improved cost-efficiencies resulting from the ongoing application of Envista Business Systems (“EBS”). We believe our deep-rooted commitment to EBS helps drive our market leadership and differentiates us in the dental products industry. EBS encompasses not only lean tools and processes, but also methods for driving growth, innovation and leadership. Within the EBS framework, we pursue a number of ongoing strategic initiatives relating to streamlining business operations, portfolio simplification, reduction of costs, redeployment of resources, customer insight generation, product development and commercialization, efficient sourcing, and improvement in manufacturing and back-office support, all with a focus on continually improving quality, delivery, cost, growth and innovation.

### Non-GAAP Measures

In order to establish period-to-period comparability, we include the non-GAAP measure of core sales in this report. References to the non-GAAP measure of core sales (also referred to as core revenues or sales/revenues from existing businesses) refer to sales calculated according to GAAP, but excluding:

- sales from acquired businesses for one year from the acquisition date;
- sales from discontinued products; and
- the impact of currency translation.

We exclude sales from acquired businesses in order to provide accurate year over year comparisons. Sales from discontinued products includes major brands or major products that we have made the decision to discontinue as part of a portfolio restructuring. Discontinued brands or products consist of those which we (1) are no longer manufacturing, (2) are no longer investing in the research or development of, and (3) expect to discontinue all significant sales of within one year from the decision date to discontinue. The portion of sales attributable to discontinued brands or products is calculated as the net decline of the applicable discontinued brand or product from period-to-period. We exclude sales from discontinued products because discontinued products do not have a continuing contribution to operations and management believes that excluding such items provides investors with a means of evaluating our on-going operations and facilitates comparisons to our peers.

The portion of sales attributable to currency translation is calculated as the difference between:

- the period-to-period change in sales; and
- the period-to-period change in sales after applying current period foreign exchange rates to the prior year period.

Core sales growth should be considered in addition to, and not as a replacement for or superior to, sales, and may not be comparable to similarly titled measures reported by other companies. We believe that reporting the non-GAAP financial measure of core sales growth provides useful information to investors by helping identify underlying growth trends in our on-going business and facilitating comparisons of our sales performance with our performance in prior and future periods and to our peers. We also use core sales growth to measure our operating and financial performance. We exclude the effect of currency translation from core sales because currency translation is not under our control, is subject to volatility and can obscure underlying business trends.

### RESULTS OF OPERATIONS

All comparisons, variances, increases or decreases discussed below are for the three and six months ended June 30, 2023, compared to the three and six months ended July 1, 2022.

*($ in millions)*

|  | Three Months Ended June 30, 2023 |  | July 1, 2022 |  | % Change |
| --- | ---: | ---: | ---: | ---: | ---: |
| Sales | $662.4 | 100.0% | $645.8 | 100.0% | 2.6% |
| Cost of sales | 283.8 | 42.8% | 276.0 | 42.7% | 2.8% |
| Gross profit | 378.6 | 57.2% | 369.8 | 57.3% | 2.4% |
| Operating costs: |  |  |  |  |  |
| Selling, general and administrative (“SG&A”) expenses | 272.9 | 41.2% | 279.5 | 43.3% | (2.4)% |
| Research and development (“R&D”) expenses | 26.8 | 4.0% | 25.1 | 3.9% | 6.8% |
| Operating profit | 78.9 | 11.9% | 65.2 | 10.1% | 21.0% |
| Nonoperating income (expense): |  |  |  |  |  |
| Other income | 7.1 | 1.1% | 0.3 | —% | NM |
| Interest expense, net | (17.4) | (2.6)% | (6.4) | (1.0)% | 171.9% |
| Income before income taxes | 68.6 | 10.4% | 59.1 | 9.2% | 16.1% |
| Income tax expense | 16.7 | 2.5% | 14.6 | 2.3% | 14.4% |
| Income from continuing operations | 51.9 | 7.8% | 44.5 | 6.9% | 16.6% |
| Income from discontinued operations, net of tax | — | —% | 2.6 | 0.4% | (100.0)% |
| Net income | $51.9 | 7.8% | $47.1 | 7.3% | 10.2% |
| Effective tax rate from continuing operations | 24.3% |  | 24.7% |  |  |

*($ in millions)*

|  | Six Months Ended June 30, 2023 |  | July 1, 2022 |  | % Change |
| --- | ---: | ---: | ---: | ---: | ---: |
| Sales | $1,289.6 | 100.0% | $1,277.2 | 100.0% | 1.0% |
| Cost of sales | 548.3 | 42.5% | 533.3 | 41.8% | 2.8% |
| Gross profit | 741.3 | 57.5% | 743.9 | 58.2% | (0.3)% |
| Operating costs: |  |  |  |  |  |
| SG&A expenses | 539.0 | 41.8% | 537.7 | 42.1% | 0.2% |
| R&D expenses | 51.3 | 4.0% | 49.5 | 3.9% | 3.6% |
| Operating profit | 151.0 | 11.7% | 156.7 | 12.3% | (3.6)% |
| Nonoperating income (expense): |  |  |  |  |  |
| Other income | 7.4 | 0.6% | 0.6 | —% | NM |
| Interest expense, net | (34.1) | (2.6)% | (12.3) | (1.0)% | 177.2% |
| Income before income taxes | 124.3 | 9.6% | 145.0 | 11.4% | (14.3)% |
| Income tax expense | 28.6 | 2.2% | 30.1 | 2.4% | (5.0)% |
| Income from continuing operations | 95.7 | 7.4% | 114.9 | 9.0% | (16.7)% |
| Income from discontinued operations, net of tax | — | —% | 7.1 | 0.6% | (100.0)% |
| Net income | $95.7 | 7.4% | $122.0 | 9.6% | (21.6)% |
| Effective tax rate from continuing operations | 23.0% |  | 20.8% |  |  |

Non-meaningful percentage change related to year-to-year comparisons are designated as NM.

### GAAP Reconciliation

### Sales and Core Sales Growth

|  | % Change Three Month Period Ended June 30, 2023 vs. Comparable 2022 Period | % Change Six Month Period Ended June 30, 2023 vs. Comparable 2022 Period |
| --- | ---: | ---: |
| Total sales growth (GAAP) | 2.6% | 1.0% |
| Plus the impact of: |  |  |
| Acquisition | (1.7)% | (2.5)% |
| Currency exchange rates | 1.2% | 1.4% |
| Core sales growth (non-GAAP) | 2.1% | (0.1)% |

Sales and core sales growth for the three months ended June 30, 2023 increased 2.6% and 2.1%, respectively, compared to the comparable period in 2022. An increase in sales volume positively impacted sales growth by 2.7% on a period-over-period basis, offset by a decrease in sales price of 0.6%. Sales in developed markets increased due to growth in Western Europe, partially offset by a decrease in North America. Sales in emerging markets increased primarily due to Eastern Europe.

Sales growth for the six months ended June 30, 2023 increased by 1.0% while core sales growth decreased by 0.1%, for the comparable period in 2022. A sales price decrease of 0.1% negatively impacted sales growth and sales volume remained flat on a period-over-period basis. Sales in developed markets decreased primarily due to North America, partially offset by an increase in Western Europe. Sales in emerging markets increased due to Eastern Europe, partially offset by a decrease in China.

### COST OF SALES AND GROSS PROFIT MARGIN

*($ in millions)*

|  | Three Months Ended June 30, 2023 | July 1, 2022 | Six Months Ended June 30, 2023 | July 1, 2022 |
| --- | ---: | ---: | ---: | ---: |
| Cost of sales | 283.8 | 276.0 | 548.3 | 533.3 |
| Gross profit margin | 57.2% | 57.3% | 57.5% | 58.2% |

The increase in cost of sales during the three and six months ended June 30, 2023 as compared to the comparable periods in 2022, was primarily due to increased sales, unfavorable product mix and the impact of higher costs due to inflation.

Gross profit margin percentages during the three and six months ended June 30, 2023 decreased compared to the comparable periods in 2022. For the three months ended June 30, 2023, the slight decrease was primarily due to unfavorable product mix and higher costs due to inflation, offset by an increase in volume and the period-over-period savings associated with productivity improvements. For the six months ended June 30, 2023, the decrease was primarily due to unfavorable product mix and higher costs due to inflation, partially offset by period-over-period savings associated with productivity improvements.

### OPERATING EXPENSES

*($ in millions)*

|  | Three Months Ended June 30, 2023 | July 1, 2022 | Six Months Ended June 30, 2023 | July 1, 2022 |
| --- | ---: | ---: | ---: | ---: |
| Selling, general and administrative expenses | $272.9 | $279.5 | $539.0 | $537.7 |
| Research and development expenses | $26.8 | $25.1 | $51.3 | $49.5 |
| SG&A as a % of sales | 41.2% | 43.3% | 41.8% | 42.1% |
| R&D as a % of sales | 4.0% | 3.9% | 4.0% | 3.9% |

32

SG&A expenses as a percentage of sales for the three and six months ended June 30, 2023 decreased as compared to the comparable periods of 2022. For the three months ended June 30, 2023, the decrease was primarily due to increased sales volume combined with lower acquisition related and sales and marketing expenses. For the six months ended June 30, 2023, the decrease was primarily due to lower acquisition related expenses combined with lower sales and marketing expenses.

R&D expenses as a percentage of sales for the three and six months ended June 30, 2023, were consistent with the comparable period in 2022.

### OTHER INCOME (EXPENSE), NET

The increase in Other income (expense), net for both the three and six months ended June 30, 2023 is primarily due to a $6.9 million gain on the sale of an equity investment.

### INTEREST COSTS AND FINANCING

Interest costs were $17.4 million and $6.4 million for the three months ended June 30, 2023 and July 1, 2022, respectively, and $34.1 million and $12.3 million for the six months ended June 30, 2023 and July 1, 2022, respectively. The increase in interest costs for the three and six months ended June 30, 2023 as compared to the comparable periods of 2022 was due primarily to higher interest rates on our variable rate Term Loan and Euro Term Loan borrowings.

### INCOME TAXES

|  | Three Months Ended June 30, 2023 | July 1, 2022 | Six Months Ended June 30, 2023 | July 1, 2022 |
| --- | ---: | ---: | ---: | ---: |
| Effective tax rate from continuing operations | 24.3% | 24.7% | 23.0% | 20.8% |

Our effective tax rate from continuing operations of 24.3% and 23.0% for the three and six months ended June 30, 2023, respectively, differed from the comparable periods in 2022 primarily due to the Company’s geographical mix of earnings and a decrease in certain discrete tax benefits.

On August 16, 2022, the U.S. enacted the Inflation Reduction Act of 2022, which, among other things, implemented a 15% minimum tax on book income of certain large corporations, a 1% excise tax on net stock repurchases, and several tax incentives to promote clean energy. Based on our current analysis of the provisions, this legislation did not have a material impact on our Condensed Consolidated Financial Statements as of or for the three and six months ended June 30, 2023.

### RESULTS OF OPERATIONS - BUSINESS SEGMENTS

### Specialty Products & Technologies

Our Specialty Products & Technologies segment primarily develops, manufactures and markets dental implant systems, including regenerative solutions, dental prosthetics and associated treatment software and technologies, as well as orthodontic bracket systems, aligners and lab products.

### Specialty Products & Technologies Selected Financial Data

*($ in millions)*

|  | Three Months Ended June 30, 2023 | July 1, 2022 | Six Months Ended June 30, 2023 | July 1, 2022 |
| --- | ---: | ---: | ---: | ---: |
| Sales | $417.0 | $407.7 | $827.0 | $804.8 |
| Operating profit | $55.7 | $74.0 | $126.8 | $144.3 |
| Operating profit as a % of sales | 13.4% | 18.2% | 15.3% | 17.9% |

33

### Sales and Core Sales Growth

|  | % Change Three Month Period Ended June 30, 2023 vs. Comparable 2022 Period | % Change Six Month Period Ended June 30, 2023 vs. Comparable 2022 Period |
| --- | ---: | ---: |
| Total sales growth (GAAP) | 2.3% | 2.8% |
| Plus the impact of: |  |  |
| Acquisitions | (2.1)% | (2.1)% |
| Currency exchange rates | 1.5% | 1.7% |
| Core sales growth (non-GAAP) | 1.7% | 2.4% |

#### Sales

Sales and core sales growth for the three months ended June 30, 2023 increased 2.3% and 1.7%, respectively, compared to the comparable period in 2022. Sales increased by 2.1% due to higher volume on a period-over-period basis, offset by a decrease in sales price of 0.4%. Sales in developed markets increased primarily due to growth in Western Europe, partially offset by a decrease in North America. Sales in emerging markets increased primarily due to Eastern Europe, partially offset by a decrease in Russia.

Sales and core sales growth for the six months ended June 30, 2023 increased 2.8% and 2.4%, respectively, compared to the comparable period in 2022. Sales increased by 2.9% due to higher volume on a period-over-period basis, slightly offset by a decrease in sales price of 0.5%. Sales in developed markets increased primarily due to growth in Western Europe, partially offset by a decrease in North America. Sales in emerging markets increased primarily due to Eastern Europe, partially offset by decreases in China and Russia.

Additionally, sales for the three and six months ended June 30, 2023 were also positively impacted by the acquisition of Osteogenics.

#### Operating Profit

Operating profit margin was 13.4% for the three months ended June 30, 2023, as compared to an operating profit margin of 18.2% for the comparable period of 2022. Operating profit margin was 15.3% for the six months ended June 30, 2023, as compared to an operating profit margin of 17.9% for the comparable period of 2022. The decrease in operating profit margin for both the three and six month periods was primarily due to unfavorable product mix, investments in our long-term growth initiatives, and the impact of inflation, partially offset by an increase in sales volume and by period-over-period savings associated with productivity improvements.

### EQUIPMENT & CONSUMABLES

Our Equipment & Consumables segment primarily develops, manufactures and markets dental equipment and supplies used in dental offices, including digital imaging systems, software and other visualization/magnification systems; endodontic systems and related consumables; restorative materials and instruments, rotary burs, impression materials, bonding agents and cements and infection prevention products.

### Equipment & Consumables Selected Financial Data

*($ in millions)*

|  | Three Months Ended June 30, 2023 | July 1, 2022 | Six Months Ended June 30, 2023 | July 1, 2022 |
| --- | ---: | ---: | ---: | ---: |
| Sales | $245.4 | $238.1 | $462.6 | $472.4 |
| Operating profit | $48.4 | 30.2 | $80.9 | $75.7 |
| Operating profit as a % of sales | 19.7% | 12.7% | 17.5% | 16.0% |

34

### Sales and Core Sales Growth

|  | % Change Three Month Period Ended June 30, 2023 vs. Comparable 2022 Period | % Change Six Month Period Ended June 30, 2023 vs. Comparable 2022 Period |
| --- | ---: | ---: |
| Total sales growth (GAAP) | 3.1% | (2.1)% |
| Plus the impact of: |  |  |
| Acquisition | (1.0)% | (3.1)% |
| Currency exchange rates | 0.8% | 0.8% |
| Core sales growth (non-GAAP) | 2.9% | (4.4)% |

#### Sales

Sales and core sales growth for the three months ended June 30, 2023 increased 3.1% and 2.9%, respectively, compared to the comparable period in 2022. Sales growth increased by 3.7% due to higher volume on a period-over-period basis, offset by a decrease in sales price of 0.8%. Sales increased for the three months ended June 30, 2023 primarily due to emerging markets.

Sales and core sales growth for the six months ended June 30, 2023 decreased 2.1% and 4.4%, respectively, compared to the comparable period in 2022. A decrease in sales volume negatively impacted sales growth by 5.1% on a period-over-period basis, offset by an increase in sales price of 0.7%. Sales decreased in developed markets primarily in North America and Western Europe, while sales increased in emerging markets.

Sales for the three and six months ended June 30, 2023 were positively impacted by the acquisition of our Intraoral Scanner Business.

#### Operating Profit

Operating profit margin was 19.7% for the three months ended June 30, 2023, as compared to an operating profit margin of 12.7% for the comparable period of 2022. The increase in operating profit margin for the three months ended June 30, 2023 was primarily due to higher sales volume, period-over-period savings associated with productivity improvements, decreased amortization of intangible assets, and lower restructuring costs, partially offset by the impact of incremental material price cost due in part to inflation.

Operating profit margin was 17.5% for the six months ended June 30, 2023, as compared to an operating profit margin of 16.0% for the comparable period of 2022. The increase in operating profit margin for the six months ended June 30, 2023 was primarily due to favorable sales price and period-over-period savings associated with productivity improvements, partially offset by lower sales volume and the impact of higher costs due to inflation.

### LIQUIDITY AND CAPITAL RESOURCES

We assess our liquidity in terms of our ability to generate cash to fund our operating and investing activities. We continue to generate substantial cash from operating activities and believe that our operating cash flow and other sources of liquidity are sufficient to allow us to manage our capital structure on a short-term and long-term basis and continue investing in existing businesses and consummating strategic acquisitions.

Following is an overview of our cash flows and liquidity, which includes the cash flows of the KaVo Treatment Unit and Instrument Business for the six months ended July 1, 2022.

### Overview of Cash Flows and Liquidity

|  | Six Months Ended June 30, 2023 | July 1, 2022 |
| --- | ---: | ---: |
| Net cash provided by operating activities | $78.2 | $25.7 |
| Payments for additions to property, plant and equipment | $(31.6) | $(31.9) |
| Proceeds from sale of equity investment | 10.7 | — |
| Acquisitions, net of cash acquired | — | (569.8) |
| Proceeds from sale of KaVo treatment unit and instrument business | — | 28.8 |
| All other investing activities, net | (3.9) | (13.6) |
| Net cash used in investing activities | $(24.8) | $(586.5) |
| Proceeds from stock option exercises | $5.9 | $15.4 |
| Tax withholding payment related to net settlement of equity awards | (6.4) | (8.1) |
| Proceeds from borrowings | — | 0.3 |
| Repayment of borrowings | — | (0.5) |
| All other financing activities | 1.6 | — |
| Net cash provided by financing activities | $1.1 | $7.1 |

#### Operating Activities

Cash flows from operating activities can fluctuate significantly from period-to-period due to working capital needs and the timing of payments for income taxes, restructuring activities, pension funding and other items impacting reported cash flows.

Net cash provided by operating activities was $78.2 million during the six months ended June 30, 2023, as compared to net cash provided by operating activities of $25.7 million for the comparable period of 2022, primarily due to lower overall net cash payments during the six months ended June 30, 2023.

#### Investing Activities

Cash flows relating to investing activities consist primarily of cash used for capital expenditures and acquisitions. Capital expenditures are made primarily for increasing capacity, replacing equipment, supporting new product development and improving information technology systems.

Net cash used in investing activities was $24.8 million for the six months ended June 30, 2023, as compared to net cash used in investing activities of $586.5 million for the comparable period in 2022, primarily due to the prior year period reflecting cash paid with respect to the Intraoral Scanner Business acquisition and the earnout from the sale of the KaVo Treatment Unit and Instruments Business, offset by the proceeds received in the current quarter related to the sale of an equity investment.

#### Financing Activities and Indebtedness

Cash flows relating to financing activities consist primarily of cash flows associated with debt borrowings and the issuance of common stock.

Net cash provided by finance activities was $1.1 million for the six months ended June 30, 2023 compared to net cash provided by financing activities of $7.1 million for the comparable period of 2022 primarily due to a reduction in cash flows associated with the issuance of common stock.

For a description of our outstanding debt as of June 30, 2023, refer to Note 13 to our Condensed Consolidated Financial Statements in this Quarterly Report on Form 10-Q.

We intend to satisfy any short-term liquidity needs that are not met through operating cash flow and available cash primarily through our revolving credit facility.

### Cash and Cash Requirements

As of June 30, 2023, we held $651.7 million of cash and cash equivalents that were held on deposit with financial institutions. Of this amount, $152.4 million was held within the United States and $499.3 million was held outside of the United States. We will continue to have cash requirements to support working capital needs, capital expenditures and acquisitions, pay interest and service debt, pay taxes and any related interest or penalties, fund our restructuring activities as required and support other business needs. We generally intend to use available cash, internally generated funds and our revolving credit facility to meet these cash requirements, but in the event that additional liquidity is required, particularly in connection with acquisitions, we may need to enter into new credit facilities or access the capital markets. We may also access the capital markets from time to time to take advantage of favorable interest rate environments or other market conditions. However, there is no guarantee that we will be able to obtain alternative sources of financing on commercially reasonable terms or at all. See “Item 1A. Risk Factors—Risks Related to Our Business” in our 2022 10-K.

Generally, cash and cash equivalents held in these financial institutions may be withdrawn or redeemed at face value, and therefore minimal credit risk exists with respect to them. Nonetheless, deposits with these financial institutions exceed the Federal Deposit Insurance Corporation (FDIC) insurance limits or similar limits in foreign jurisdictions, to the extent such deposits are even insured in such foreign jurisdictions. While we monitor on a systematic basis the cash and cash equivalent balances in the operating accounts and adjust the balances as appropriate, these balances could be impacted if one or more of the financial institutions with which we deposit our funds fails or is subject to other adverse conditions in the financial or credit markets. To date, we have experienced no loss of principal or lack of access to our invested cash or cash equivalents; however, we can provide no assurance that access to our cash and cash equivalents will not be affected if the financial institutions where we hold our cash and cash equivalents fail.

While repatriation of some cash held outside the United States may be restricted by local laws, most of our foreign cash could be repatriated to the United States. Following enactment of the Tax Cut and Jobs Act of 2017 (“TCJA”) and the associated transition tax, in general, repatriation of cash to the United States can be completed with no incremental U.S. tax; however, repatriation of cash could subject us to non-U.S. jurisdictional taxes on distributions. The cash that our non-U.S. subsidiaries hold for indefinite reinvestment is generally used to finance foreign operations and investments, including acquisitions. The income taxes, if any, applicable to such earnings including basis differences in our foreign subsidiaries are not readily determinable.

As of June 30, 2023, we believe that we have sufficient sources of liquidity to satisfy our cash needs over the next 12 months and beyond, including our cash needs in the United States.

There were no material changes to our contractual obligations during the three and six months ended June 30, 2023.

### Off-Balance Sheet Arrangements

There were no material changes to the Company’s off-balance sheet arrangements described in the 2022 10-K that would have a material impact on the Company’s Condensed Consolidated Financial Statements.

### Debt Financing Transactions

For a description of our outstanding debt as of June 30, 2023, refer to Note 13 to our Condensed Consolidated Financial Statements in this Quarterly Report on Form 10-Q.

### CRITICAL ACCOUNTING ESTIMATES

There were no material changes to our critical accounting estimates described in the 2022 10-K that have had a material impact on our Condensed Consolidated Financial Statements.

The extent of the impact of the COVID-19 pandemic on our business is highly uncertain and difficult to predict. If actual results are not consistent with management’s estimates and assumptions used for valuation allowances, contingencies, potential impairments, revenue recognition and income taxes, the related account balances may be overstated or understated and a charge or credit to net income may be required.

## Market risk

As filed, 351 characters.

Quantitative and qualitative disclosures about market risk appear in “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Qualitative and Quantitative Disclosures About Market Risk,” in our 2022 10-K. There were no material changes to this information reported in our 2022 10-K during the quarter ended June 30, 2023.

## Controls and procedures

As filed, 1,007 characters.

#### Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our President and Chief Executive Officer, and Senior Vice President and Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act), as of the end of the period covered by this report. Based on such evaluation, our President and Chief Executive Officer, and Senior Vice President and Chief Financial Officer, have concluded that, as of the end of such period, our disclosure controls and procedures were effective.

#### Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the quarter ended June 30, 2023 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

## Risk factors

As filed, 608 characters.

There have been no material changes from the risk factors disclosed in Part I, “Item 1A. Risk Factors,” of our 2022 Form 10-

K. You should carefully consider the factors discussed in Part I, “Item 1A. Risk Factors” in our 2022 10-K, which could materially affect our business, financial position, or future results of operations. The risks described in our 2022 10-K, are not the only risks we face. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial position, or future results of operations.

Filed Aug 2, 2023.
Source: SEC EDGAR, the filing index for accession 0001757073-23-000060. Last ingested by Listed: Nov 14, 2026, 11:59 ET. No prices; not investment advice.
